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Control and Prevention of Rubella:
Evaluation and Management of Suspected Outbreaks,
Rubella in Pregnant Women, and Surveillance
for Congenital Rubella Syndrome
Summary
Outbreaks of rubella continue to occur in the United States despite widespread
use of the measles-mumps-rubella (MMR) vaccine. Throughout the mid- to late-
1990s, rubella outbreaks were characterized by increased numbers of cases
among adults born in countries that do not have or have only recently instituted
a national rubella vaccination program. To address this change in disease
epidemiology, CDC’s National Immunization Program (NIP) developed the
following recommendations in conjunction with public health officials in the field.
Public health officials should implement appropriate responses to reports of
suspected rubella to determine if an outbreak exists, evaluate its scope, and
implement appropriate control measures. Health-care providers should be aware
of the need for rubella prevention and control among women of childbearing age
and of the appropriate follow-up for pregnant women exposed to rubella.
Comprehensive surveillance for congenital rubella syndrome should begin
during a rubella outbreak.
INTRODUCTION
Since the licensure of the rubella vaccine in 1969, the number of cases of rubella in
the United States has decreased 99%, from 57,686 cases in 1969 to 271 cases in 1999
(CDC, unpublished data, 2000). The epidemiology of rubella changed in the 1990s, in-
cluding shifts in the age distribution, ethnicity, and country of origin of patients, and in
the setting of outbreaks. During the early 1990s, most rubella cases in the United States
occurred among persons aged <15 years; since the mid-1990s, persons aged >15 years
have accounted for most reported cases. In 1999, adults accounted for 86% of cases, an
increase from 41% in 1990, and 73% of persons with rubella were Hispanic, compared
with 4% in 1991 (CDC, unpublished data, 2000). Most of these persons were foreign-
born. In recent rubella outbreaks, most cases occurred among persons from Mexico
and Central America. Moreover, outbreaks occurred predominantly in workplaces and
communities; before the mid-1990s, outbreaks occurred mainly in religious communi-
ties, schools, jails, and other closed environments. Recently, rubella outbreaks have
been identified in poultry and meat processing plants that employ large numbers of
foreign-born workers.
The number of cases of congenital rubella syndrome (CRS) has also declined, and
CRS now disproportionately affects infants born to foreign-born women. During 1997–
1999, a total of 21/26 (81%) infants reported with CRS were Hispanic, and 24/26 (92%)
were born to foreign-born mothers (CDC, unpublished data, 2000). Although informa-
tion on country of origin was not collected in 1991, a total of 8/42 (19%) infants with CRS
were Hispanic. Identifying and managing susceptible pregnant women who might have
been exposed to rubella is challenging, especially in communitywide outbreaks.
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Congenital rubella infection (CRI) encompasses all outcomes associated with in-
trauterine rubella infection, including miscarriage, stillbirth, abortion, combinations of
birth defects, or asymptomatic infection in the infant (also known as infection only) (1 ).
Although serologic testing remains the most available laboratory method for confirma-
tion, CRI also can be confirmed by reverse transcriptase polymerase chain reaction (RT-
PCR) assays, which detect rubella virus (2 ).
Making best use of available technology will help rubella virus surveillance and
ascertainment. For example, molecular typing of rubella virus is available to identify
the origin of the virus as well as which virus strains are circulating. This information is
necessary to document elimination of indigenous transmission. Universal programs to
screen newborn hearing in the United States could help improve ascertainment of CRS
cases because hearing impairment is the most common single defect associated with
CRS (3 ). Performing serologic testing for rubella on infants who fail hearing screenings
at birth could help identify CRS cases.
This report describes seven steps for evaluating and managing suspected rubella
outbreaks. They were developed by NIP in conjunction with state and local public health
officials based on experience with recent outbreaks in the United States (4,5 ). These
steps are a) consider a single case of rubella a potential outbreak, b) confirm the diag-
nosis, c) conduct case investigations and vaccinate susceptible contacts, d) enhance
active and passive surveillance measures, e) implement rubella control measures, f)
conduct outreach in affected facilities and communities, and g) develop a plan for pre-
venting future rubella outbreaks. This report also provides guidelines for evaluating
and managing rubella in pregnant and nonpregnant women and evaluating infants for CRI.
BACKGROUND
Rubella is usually a mild febrile rash illness in adults and children. Other symptoms
include lymphadenopathy, malaise, or conjunctivitis. Arthralgia and arthritis can occur
in <70% of infected adult and adolescent females. Rare complications are thrombocy-
topenic purpura, encephalitis, neuritis, and orchitis. The incubation period for rubella is
12–23 days, and 20%–50% of rubella infections are asymptomatic. Persons with rubella
are most infectious when rash is erupting, but can shed virus from 7 days before to 5–
7 days after rash onset (i.e., the infectious period).
The most serious consequences of rubella result from infection during the first tri-
mester of pregnancy. Rubella infection can affect all organs in the developing fetus and
cause miscarriage, fetal death, and congenital anomalies. Up to 90% of infants born to
mothers infected during the first 11 weeks of gestation will develop a pattern of birth
defects called CRS (6 ); the rate of CRS for infants born to women infected during the
first 20 weeks of pregnancy is 20%. Infants infected with rubella late in gestation do not
exhibit clinical manifestations of CRS. Any infant infected with rubella in utero can shed
virus for <1 year, sometimes longer (7 ).
The goal of the rubella vaccination program is to prevent the consequences of infec-
tion during pregnancy. Many countries do not have rubella vaccination programs or
have only recently implemented such programs, and many adults throughout the world
remain susceptible. In 1996, the World Health Organization (WHO) estimated that 36%
of member countries offered routine rubella vaccination (8 ). In 1999, WHO estimated
that 52% of countries offered routine rubella vaccination; in the Region of the Ameri-
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cas, 89% of countries used rubella vaccine (9 ). Adults in the United States who were
born in countries where routine rubella vaccination was not offered are at higher risk
for contracting rubella and having infants with CRS compared with adults born in the
United States. Vaccinating foreign-born, susceptible adults can be challenging because
they might have little or no contact with the U.S. health-care system. Thus, health-care
providers who treat foreign-born adults should document their rubella immunity with
a written record of a rubella-containing vaccine or by serologic testing. If problems
arise in translating vaccination records from other countries, help is available from the
CDC Immunization Information Hotline at (800) 232-2522 (English) or (800) 232-0233
(Spanish). WHO also has summarized current global vaccination policies for countries
throughout the world (10 ).
Adequate proof of rubella immunity includes a) written documentation of receipt of
>1 dose of a rubella-containing vaccine administered on or after the first birthday, b)
laboratory evidence of immunity, or c) birth before 1957 (except for women who could
become pregnant). However, during an outbreak, persons born before 1957 should not
automatically be considered immune to rubella. Rubella immunity is defined as a he-
magglutination inhibition antibody titer of >1:8, a hemolysis in gel result of >10 interna-
tional units (IU), or an optical density by enzyme-linked immunoassay (EIA) above the
limit set by the manufacturer (11 ). Persons who do not meet the above criteria are
considered susceptible.
REPORTING
Rubella and CRS became notifiable diseases in the United States in 1966 and 1969,
respectively. All 50 states require reporting of rubella and CRS (12 ). For information on
these requirements, contact local or state health departments.
State and local health departments rely on health-care providers, laboratory per-
sonnel, and other public health workers to report confirmed, probable, and suspected
cases of rubella and CRS so the departments can monitor the occurrences of these
diseases and facilitate appropriate control measures. Health-care providers and labora-
tory personnel who suspect cases of rubella, CRS, or congenital rubella infection only
should report them within 24 hours to their local health department. Health-care
providers should not delay reporting suspected cases of rubella, CRS, and congenital
rubella infection only while they wait for laboratory confirmation.
Criteria for Rubella Case Classification
A clinical case of rubella is defined as an illness characterized by a) acute onset of
generalized maculopapular rash; b) temperature >37.2 C (>99.0 F), if measured; and c)
arthralgia/arthritis, lymphadenopathy (usually suboccipital, postauricular, and cervical),
or conjunctivitis. Case classification for rubella is based on a clinical case definition and
laboratory criteria for diagnosis (13 ). Cases are classified into one of the following
categories:
• Suspected. Any generalized rash illness of acute onset.
• Probable. A case that meets the clinical case definition, has no or noncontributory
serologic or virologic testing, and is not epidemiologically linked to a laboratory-
confirmed case.
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• Confirmed. A case that is laboratory confirmed or that meets the clinical case
definition and is epidemiologically linked to a laboratory-confirmed case.
• Asymptomatic Confirmed. A laboratory-confirmed case in a person who is
asymptomatic that also is epidemiologically linked to a laboratory-confirmed case
clinically consistent with rubella (14 ).
Cases are also categorized by importation status:
• Indigenous. Any case that cannot be proved to be imported.
• State-to-State Importation. Requires documentation that a person either had
face-to-face contact with a case of rubella outside the state or was out of the state
for the entire period when he or she might have become infected (i.e., 14–23 days
before rash onset).
• International Importation. A case that has its source outside the United States
with onset of rash within 14–23 days of entry into this country.
Laboratory Diagnosis of Rubella
Laboratory diagnosis of rubella requires any one of the following:
• A positive serologic test for rubella immunoglobulin M (IgM) antibody. The
preferred testing method for IgM is EIA, using the capture technique; indirect
assays are acceptable (15 ). IgM antibodies might not be detectable before 4–5
days after rash onset, but they can persist for 6 weeks after rash onset. If negative
results are obtained from a specimen taken before 4–5 days after rash onset,
another specimen should be taken as soon as possible thereafter. Serum rubella
IgM test results that are false positive have been reported in persons with other
viral infections (e.g., acute infection with Epstein-Barr virus [infectious
mononucleosis], recent cytomegalovirus infection, and parvovirus infection) or in
the presence of rheumatoid factor. Patients with laboratory evidence of recent
measles infection are excluded because concurrent infections are unlikely.
• A significant rise in serum rubella immunoglobulin G (IgG) antibody level
between acute- and convalescent-phase titers by any standard serologic assay.
Sera for IgG testing should be collected as early as possible (within 7–10 days)
after onset of illness and again >7–14 days (preferably 2–3 weeks) later.
• Isolation of rubella virus from nasal, blood, throat, urine, or cerebrospinal fluid
specimens (best results come from throat swabs). Specimens should be obtained
as soon as possible (within 4 days) after rash onset. Efforts should be made to
obtain clinical specimens for virus isolation from all patients (or from some
patients in each outbreak) at the time of the initial investigation (14 ).
• Detection of virus by RT-PCR. This process can be used to detect the presence of
rubella virus after growth in tissue culture or directly in clinical specimens.
Specimens submitted for rubella virus isolation or detection by RT-PCR can also be
used for molecular typing. Molecular typing can help determine a) the origin of the
virus, b) which virus strains are circulating in the United States, and c) whether these
strains have become endemic in the United States. Specimens for molecular typing
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should be obtained as soon as possible after diagnosis. Appropriate specimens include
throat swabs and cerebrospinal fluid. Specimens for molecular typing should be sent
to CDC as directed by the state health department. For information on the procedure
for obtaining specimens, contact CDC’s National Center for Infectious Diseases, Respi-
ratory and Enterovirus Branch, Measles Virus Section at (404) 639-3512.
Laboratory Procedures for Persons Exposed to Rubella
Who Do Not Have Rash
Persons exposed to rubella, particularly pregnant women, should be tested for ru-
bella infection. Asymptomatic rubella infection can be diagnosed by a positive rubella-
specific IgM antibody test or a significant rise in IgG antibody level between acute- and
convalescent-phase tests. The acute-phase IgG serum specimen should be collected as
soon as possible after exposure, whereas the convalescent-phase IgG specimen should
be collected >7–14 days (preferably 2–3 weeks) later.
Case Classification Criteria for Congenital Rubella Syndrome*
CRS results from rubella infection in utero, usually manifests in infancy, and is char-
acterized by clinical signs or symptoms from the following categories:
a) Cataracts/congenital glaucoma, congenital heart disease (most commonly
patent ductus arteriosus or peripheral pulmonic stenosis), hearing impairment,
pigmentary retinopathy.
b) Purpura, hepatosplenomegaly, jaundice, microcephaly, developmental delay,
meningoencephalitis, radiolucent bone disease.
Infants with CRS usually present with more than one of these signs or symptoms.
However, infants may present with a single defect. Hearing impairment is the most
common single defect.
Case classification for CRS is based on clinical findings and laboratory criteria for
diagnosis (13 ). Cases are classified as follows:
• Suspected. A case with some consistent clinical findings but not meeting the
criteria for a probable case.
• Probable. A case that is not laboratory confirmed and that has any two findings
listed in paragraph a) of the clinical description or one finding from paragraph a)
and one from paragraph b), and lacks evidence of any other etiology.
• Confirmed. A clinically consistent case that is laboratory confirmed.
• Infection Only. A case that demonstrates laboratory evidence of infection, but
without any clinical symptoms or signs.
CRS cases are also categorized by importation status:
• Indigenous Case. Any case that cannot be proved to be imported.
• State-to-State Importation. Requires documentation that the mother either had
face-to-face contact with a case of rubella outside the state or was out of state for
*Most of the wording in this section comes directly from the case definitions developed by CDC
and the Council of State and Territorial Epidemiologists (CSTE) (CDC. Case definitions for
infectious conditions under public health surveillance. MMWR 1997;46[No. RR-10]:30).
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the entire period when she might have become infected (14–23 days before rash
onset or 21 days before conception and during the first 20 weeks of gestation).
• International Importation. Defined as CRS in a U.S. or non-U.S. citizen whose
mother was outside the United States for the entire period when she may have
had exposure to rubella (21 days before conception and during the first 20 weeks
of gestation), or who has known exposure to rubella risks outside the United
States.
Laboratory Diagnosis of Congenital Rubella Syndrome
and Congenital Rubella Infection Only
Laboratory diagnosis of CRS or congenital rubella infection only requires any one of
the following:
• Demonstration of a rubella-specific IgM antibody or infant IgG rubella antibody
level that persists at a higher level and for a longer time than expected from
passive transfer of maternal antibody (i.e., rubella titer that does not drop at the
expected rate of a twofold dilution per month). Approximately 20% of infected
infants tested for rubella IgM might not have detectable titers before age 1 month
(L.Z. Cooper, M.D., Columbia University, oral communication, 1998). Thus, infants
with symptoms consistent with CRS who test negative soon after birth should be
retested at age 1 month.
• Isolation of rubella virus, which can be obtained from nasal, blood, throat, urine,
or cerebrospinal fluid specimens (best results come from throat swabs). Efforts
should be made to obtain clinical specimens for virus isolation from infants at the
time of the initial investigation. However, infants with CRS and congenital rubella
infection only shed virus and are considered infectious for a prolonged period.
Children with CRS should be presumed infectious at least through age 1 year
unless nasopharynx and urine cultures are negative for virus after age 3 months.
Some authorities suggest that an infant with CRS should be considered infectious
until two cultures of clinical specimens obtained 1 month part are negative for
rubella virus.
• Detection of virus by RT-PCR. This process can be used to detect the presence of
rubella virus after growth in tissue culture or directly in clinical specimens.
Specimens for molecular typing should be obtained from infants with CRS as soon
as possible after clinical diagnosis. Appropriate specimens include throat swabs, cere-
brospinal fluid, and cataracts from surgery. Specimens for molecular typing should be
sent to CDC as directed by the state health department.
RECOMMENDATIONS
The seven steps described in this section are recommended for the evaluation,
management, and surveillance of suspected rubella outbreaks (Box). They are based
on recent experience with outbreaks in the United States (4,5 ). These recommenda-
tions can be used in settings beyond those discussed in this report.
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Consider a Single Case of Rubella a Potential Outbreak
Because the incidence of rubella is low in the United States, health agencies should
consider even one case a potential outbreak. Rubella is an infectious disease for which
20%–50% of cases are asymptomatic, and investigation of an apparently isolated case
could reveal additional cases. Rubella transmission can occur in congregate settings
such as households, workplaces, universities, jails, or communities. The type and size
of the outbreak determines the magnitude of the response.
Most recent rubella outbreaks were first identified in the workplace. Facilities that
employ many foreign-born workers (e.g., meat or poultry processing plants) are at
greater risk for rubella outbreaks than those with mostly workers born in the United
States. Initial reports can come from on-site health-care providers who have recently
seen rash illness among employees.
Steps to Improve Ascertainment of Rubella Cases in the Workplace
• Search on-site medical logs for rash illness and payroll or sick leave
documentation for workers who might have been absent because of illness.
• Conduct follow-up interviews with workers who have been sick and contacts to
determine history of recent rash illness.
Steps to Improve Ascertainment of Rubella Cases in the Community
Recently, investigations of workplace outbreaks have revealed spread to the com-
munity. The following steps can help identify cases in the community:
• Review the community demographics to determine if there are groups at high risk
for not being vaccinated (e.g., foreign-born persons or members of religious
communities opposed to vaccination).
• Search medical records of the community’s health-care providers and hospital
emergency rooms.
• Contact schools and day care centers to identify absences caused by rash illness.
BOX. Summary of the seven steps for evaluating and managing suspected outbreaks
of rubella
• Consider a single case of rubella a potential outbreak.
• Confirm the diagnosis.
• Conduct case investigations and vaccinate susceptible contacts.
• Enhance active and passive surveillance measures.
• Implement rubella control measures.
• Conduct outreach in affected facilities and communities.
• Develop a plan for preventing future rubella outbreaks.
8 MMWR July 13, 2001
• Conduct thorough follow-up investigation of patient contacts, including
household residents, students, and teachers.
Confirm the Diagnosis
Because rubella has many symptoms in common with other rash illnesses, labora-
tory confirmation is required for case confirmation. Laboratory testing should be con-
ducted for all suspected cases of rubella. IgM antibodies might not be detectable before
4–5 days after rash onset. If negative rubella IgM and IgG results are obtained from
specimens taken before 4–5 days, repeat serologic testing (14 ).
Conduct Case Investigations
and Vaccinate Susceptible Contacts
Case investigation and identification of contacts should be conducted for all sus-
pected cases of rubella. In addition, asymptomatic confirmed cases should be investi-
gated and contacts identified. A descriptive analysis of an outbreak allows health
agencies to focus control measures — especially vaccination — on persons most in
need. Cases of rubella occurring in vaccinated persons within 7–10 days after vaccina-
tion should be investigated, and specimens should be obtained for virus isolation to
determine if rash is attributable to vaccine virus or wild virus.
Any direct contact with a patient with rubella during the infectious period (i.e., 7 days
before to 5–7 days after rash onset) is defined as exposure. Contact can include (but is
not limited to) living in the same household, attending the same class or social func-
tion, or working side-by-side on a production line. Although rubella transmission is
usually associated with repeated exposure, transmission has been documented after a
single exposure.
Depending on resources available, investigation of contacts of patients with rubella
might need to be prioritized based on the probability of transmission. The first priority
should be persons who share households or persons in a congregate environment
who share space (e.g., side-by-side workers on a production line) with a patient. The
second priority should be persons who share or have shared environments with a po-
tential for contact (e.g., places of worship, parties, social gatherings), but who did not
knowingly have direct contact with a patient. If resources allow, investigation of con-
tacts can be extended to geographic areas or groups at risk where disease has been
documented.
Every effort should be made to identify all susceptible pregnant women who might
have been exposed to a patient and test them for rubella immunity. For example, in a
workplace outbreak, pregnant women who have contact with patients (including co-
workers and household contacts) should be evaluated for rubella immunity. In
communitywide outbreaks, health-care workers who treat pregnant women should be
alerted to the outbreak and advised to verify rubella immunity in pregnant women.
Steps for Locating Exposed Contacts for Further Investigation
• Record symptom onset date and infectious period for patients on a calendar to
determine in what setting the exposure might have occurred, where to look for
other exposed persons, and who suspected patients had contact with during their
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infectious period. For example, if a person had rash onset January 26, exposure
would have occurred 12–23 days earlier (i.e., January 3–14). The patient would
have been infectious from 7 days before to 5–7 days after rash onset (i.e., January
19–February 3). Consider asymptomatic confirmed patients infectious 5–30 days
after the last exposure.
• Use the calendar to list contacts identified during the infectious period.
• Follow up with contacts to assess symptoms of rubella-like illness, determine
susceptibility, and vaccinate susceptible persons without adequate proof of
immunity and who have no contraindications to rubella vaccine.
• Continue to investigate contacts of subsequently identified patients. (See Rubella
Prevention and Control Among Women of Childbearing Age for information on
follow-up of pregnant contacts.)
Information That Should be Obtained from Patients With Rubella
• Name, address, and telephone number(s) to reach the patient after the initial
interview, if necessary.
• Demographic information, including country of origin, length of time in the United
States, and length of time in the state where the rubella diagnosis was made.
• Primary language spoken.
• Clinical details, including the following:
— Date of onset and duration of rash.
— Presence of other symptoms (e.g., fever, arthralgia/arthritis, lymphadenopa-
thy, conjunctivitis) and date of onset.
— Complications (e.g., encephalitis, thrombocytopenia, death).
• Vaccination status, including the following:
— Number of doses of rubella vaccine.
— Dates of vaccination.
— If not vaccinated, reason for nonvaccination.
• Risk factors for disease, including the following:
— Contact with a probable or confirmed patient or a person with a rash illness
suspected of being rubella.
— Transmission setting (e.g., day care center, school, workplace, place of
worship, athletic event, or other congregate or social gathering).
— Relationship to outbreak (i.e., whether case is sporadic or part of an identified
outbreak).
— Travel history.
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— Contact with others who have recently traveled (i.e., import status [indigenous,
state-to-state, or international], state name, and country name [and state within
the country]).
• Information regarding contacts during the infectious period (i.e., 7 days before to
5–7 days after rash onset), including the following:
— List of persons with household contact (e.g., residents and others with close
contact in the home) and persons with contact in a congregate environment
with shared space.
— List of women who are pregnant who have had contact with a patient with
rubella.
— Rubella symptoms (e.g., rash, fever, lymphadenopathy) of contacts.
— Place of employment of contacts.
• Laboratory information, including the following:
— Date and source of specimen sent for viral culture (e.g., throat, urine, blood).
— Viral culture results (positive or negative for rubella virus).
— Serologic test results for serum rubella IgM or IgG, with specific titer results
when applicable (e.g., 1:256). A positive serum rubella IgM or a significant rise
between acute- and convalescent-phase IgG titers indicates an acute infection.
• Pregnancy status of female patients, including the following:
— Whether pregnant.
— If patient is pregnant, obtain information regarding a) number of weeks of
gestation at onset of illness; b) previous evidence or date of serological
immunity; c) previously diagnosed rubella infection and date; d) date and
specific titer result of previous serum rubella IgG titer; and e) pregnancy
outcome, when available.
Enhance Active and Passive Surveillance Measures
For this step, outbreak investigators should institute surveillance measures designed
to identify cases prospectively, as well as any cases with rash onset that preceded the
first identified case. Because some persons with rubella do not have rash, these mea-
sures should use a broader definition of suspected cases (e.g., fever with lymphaden-
opathy or arthralgia/arthritis in adult women) in areas where rubella cases have been
confirmed. Broadening the case definition and investigating suspected cases could lead
to more complete ascertainment.
Components of Surveillance for Rubella in an Outbreak Setting
• Identify health-care providers and facilities serving populations at risk and involve
them in surveillance.
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• Identify workplaces with large numbers of persons who might lack rubella
immunity and involve them in surveillance.
• Identify day cares, schools, places of worship, and community organizations
(particularly in neighborhoods where many residents might lack rubella
immunity) and involve them in surveillance.
• Promote awareness among health-care providers that rubella and CRS still occur
in the United States among certain groups that lack rubella immunity.
• Distribute written guidelines instructing health-care providers to obtain
appropriate serology and specimens and to notify health departments of all
suspected rubella cases.
• Establish routine contact (e.g., daily or weekly) with hospitals, doctors’ offices,
clinics, schools, and laboratories to obtain reports of persons with rash illness or
other symptoms indicative of rubella.
In addition to prospective surveillance, retrospective case finding should be con-
ducted for 6 weeks (i.e., two incubation periods) before the first identified case. If evi-
dence indicates that the outbreak was in progress during this time, retrospective case
finding should continue until no further cases are identified.
Steps to Identify Cases Retrospectively
• Review medical records in health-care settings, including doctors’ offices, for
rubella-like illness.
• Review workplace or school absentee logs.
• Review records of laboratories that conduct testing for the area.
Implement Rubella Control Measures
During a rubella outbreak, the following control measures should be taken:
• Isolate patients for 5–7 days after rash onset.
• Identify and vaccinate susceptible persons who have no contraindications to
rubella vaccine.
• Ensure that pregnant women who are exposed to rubella and do not have
adequate proof of immunity are serologically evaluated for rubella-specific IgM
and IgG antibodies (see Laboratory Diagnosis of Rubella).
• Counsel susceptible pregnant women regarding the risks for intrauterine rubella
infection and recommend that they restrict their contact with persons with
confirmed, probable, or suspected rubella for >6 weeks (two incubation periods)
after rash onset in the last identified patient. Pregnant women should also be
advised to avoid activities where they might be exposed to rubella for 6 weeks
(two incubation periods) after the onset of symptoms of rubella in the last patient
for whom rubella cannot be ruled out to minimize their chances of coming in
contact with persons with symptomatic or asymptomatic rubella infection (see
Rubella Prevention and Control Among Women of Childbearing Age).
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Control Measures for Specific Settings
Congregate Environments. Congregate environments include households, jails, day
cares, schools, military settings, workplaces, places of worship, athletic events, and
other social gatherings. Control measures recommended for these settings are as fol-
lows:
• Refer persons without adequate proof of rubella immunity for vaccination or offer
on-site vaccination clinics. After vaccination, these persons no longer need to
restrict contact. The exception is health-care workers (see Health-Care Settings).
• Isolate patients during their infectious period (i.e., 5–7 days after rash onset).
Recommend that patients restrict contact with pregnant women and persons
without adequate proof of rubella immunity for 5–7 days after rash onset.
• Recommend for day cares and schools that persons exempt from rubella
vaccination for medical, religious, or other reasons be excluded from attendance
for 3 weeks after onset of rash in the last reported patient in the outbreak setting.
• Recommend that all susceptible persons who were not vaccinated as part of the
control efforts (e.g., those who refused vaccination or who had contraindications
to vaccine) minimize contact with patients for 5–7 days after rash onset.
• Recommend that susceptible pregnant women not attend activities, particularly
in the first trimester of pregnancy, where they might be exposed to rubella for >6
weeks (two incubation periods) after the onset of symptoms of rubella in the last
patient for whom rubella cannot be ruled out to minimize their chances of coming
in contact with persons with asymptomatic rubella infection.
Health-Care Settings. Health-care settings include hospitals, doctors’ offices, clin-
ics, nursing homes, and other facilities where patients receive subacute or extended
care. Control measures recommended for these settings include excluding and vacci-
nating health-care workers without adequate evidence of immunity, particularly in set-
tings where pregnant women could be exposed.
All persons who work in health-care facilities or who have contact with any patients
should be immune to rubella. Any exposed health-care worker who does not have
adequate evidence of immunity should be excluded from duty beginning 7 days after
exposure to rubella and continuing through either a) 21 days after last exposure or
b) 5–7 days after rash appears. Susceptible, exposed health-care workers who are vac-
cinated should be excluded from direct patient care for 23 days (i.e., the longest incuba-
tion period) after the last exposure to rubella because no evidence exists that
postexposure vaccination is effective in preventing rubella infection in persons already
infected at the time of vaccination. Because birth before 1957 does not guarantee im-
munity, health-care facilities should strongly recommend a dose of MMR vaccine to
workers born before 1957 who do not have serologic evidence of immunity.
Communitywide Rubella Outbreaks. When communitywide outbreaks occur, the
following steps are recommended:
• Attempt to ensure proper isolation procedures for all patients. In general, any
person exposed to a patient with rubella or CRS who cannot demonstrate proof of
immunity should receive vaccine or restrict contact with patients with rubella or
CRS.
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• Make every effort to identify and test all exposed pregnant women. In
communitywide outbreaks, health-care workers who treat pregnant women
should be alerted to the outbreak and advised to verify rubella immunity in
pregnant women (see Rubella Prevention and Control Among Women of
Childbearing Age).
Conduct Outreach in Affected Facilities and Communities
Outreach activities should begin during the outbreak investigation and should con-
vey the seriousness of rubella infection and the importance of rubella vaccination and
other control efforts. Outreach activities also provide an opportunity to reinforce the
importance of persons seeking medical advice for rubella-like illnesses and of health-
care workers reporting rubella.
Workplace
In the workplace, outreach activities should focus on educating workers and em-
ployers regarding rubella and its consequences, using such strategies as educational
sessions, flyers, letters, and E-mail. Stress that persons who work in a place where an
outbreak is in progress and who live with or have contact with someone who is preg-
nant should be vaccinated unless known to be immune.
Community
A communitywide outbreak can be most effectively contained if public health agen-
cies form partnerships with community leaders, health-care providers, and groups with
a history of effective community involvement. These persons can act as liaisons be-
tween public health agencies and the community. Outreach activities in the community
should include the following:
• Identifying persons in the community who can serve as liaisons between public
health agencies and the local population (e.g., community activist groups,
members of the foreign-born community, health-care workers who treat migrant
populations, and leaders in places of worship).
• Training these liaisons on the current epidemiology and clinical symptoms of
rubella, as well as laboratory testing methods (for health-care providers). Stress
the importance of vaccinating persons who are susceptible to rubella, particularly
persons who live in households with pregnant women or any women of
childbearing age.
• Working with liaisons to develop targeted education messages and materials that
address community members’ beliefs regarding health care. Distribute messages
and materials where community members who are at risk are likely to have access
to them.
• Encouraging liaisons to participate in surveillance activities (e.g., they could be
aware of persons in community organizations who have missed activities because
of illness).
• Establishing vaccination sites in areas frequented by the local population (e.g.,
places of worship, day labor pick-up sites, worksites, or places where special
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celebrations are held) and providing counseling on the importance of rubella
vaccination. Bilingual personnel might be needed to serve as counselors and
investigators at these sites.
Develop a Plan for Preventing Future Rubella Outbreaks
Prevention of future rubella outbreaks includes ensuring high levels of rubella im-
munity, vaccinating susceptible persons, maintaining rubella and CRS surveillance and
reporting, and preparing an appropriate and rapid response when a case of rubella is
identified. To make the most effective use of resources to prevent CRS and control
rubella, state and local health authorities might want to identify and prioritize counties
and communities in order of decreasing risk and conduct vaccination or education cam-
paigns accordingly. Depending on cost and available resources, health department
personnel might decide to target all counties and communities in the state or limit the
campaigns to those at highest risk for rubella outbreaks based on known or suspected
susceptibility patterns and the likelihood of introduction of rubella into the community.
Based on the current epidemiology of rubella, counties most at risk appear to be those
with substantial numbers of adolescents and young adults born and raised in countries
that do not have a history of routine rubella vaccination.
All states should conduct activities for the prevention of CRS or CRI, including the
following:
• Identifying women of childbearing age at risk for rubella infection and ensuring
immunity in women by enhancing existing programs (e.g., prenatal testing and
postpartum vaccination). Approximately 50% of CRS cases could be prevented
through postpartum vaccination of women known to be susceptible to
rubella (16 ).
• Maintaining rubella surveillance and investigating contacts of patients
appropriately.
• Providing ethnically and linguistically appropriate rubella educational materials
where persons susceptible to rubella might congregate (e.g., worksites, health
clinics, WIC* centers, and community centers).
• Ensuring that MMR vaccine is available to providers through the Vaccines for
Children (VFC) program or the 317 Immunization Grant Program (under the Public
Health Service Act). For more information on these programs, contact CDC’s
National Immunization Program, Immunization Services Division, Program
Operations Branch at (404) 639-8215.
In addition, states that have had recent rubella outbreaks or a recent indigenous
CRS case or that have identified populations at high risk for rubella outbreaks might
want to emphasize rubella control as well as CRS prevention through the following
activities:
• Ensuring immunity among all persons (male and female), especially foreign-born
persons who are not likely to have received rubella vaccination.
*Special Supplemental Nutrition Program for Women, Infants, and Children.
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• Educating providers, especially VFC providers, regarding the potential increased
risk for rubella susceptibility among foreign-born persons and ensuring that
providers recommend vaccine for susceptible persons.
At workplaces where recent rubella outbreaks have occurred or high numbers of
persons at risk for rubella are employed, state health departments should
• educate management and workers regarding the risks for rubella and CRS.
• recommend that all employees susceptible to rubella receive MMR vaccine.
• recommend that rubella immunization be provided in the workplace. Some states
might consider conducting projects to demonstrate the feasibility of rubella
immunization in the workplace.
• ensure that workers who are vaccinated receive personal immunization record
cards.
• ensure that family members and close personal contacts of susceptible workers
are referred to the health department or other provider for immunization.
In communities that have had recent rubella outbreaks or where large numbers of
persons at risk for rubella reside, state health departments should
• identify leaders in communities at risk to serve as spokespersons for rubella
control and CRS prevention programs;
• work with community groups (i.e., civic or faith-based organizations) to conduct
education programs and vaccination campaigns;
• encourage employers to establish a rubella screening and vaccination program
for all current and new employees; and
• provide necessary vaccines for group members at risk identified in public health
clinics.
• alert other state health departments of rubella outbreaks, particularly those with
evidence of state-to-state importation.*
VACCINE
This section summarizes information available in the most recent ACIP statement
on MMR vaccination (17 ). In the United States, most rubella vaccination is adminis-
tered as part of the MMR vaccine. Approximately 21–28 days are required for develop-
ment of protection following vaccination.
Persons generally are presumed immune to rubella if they a) have documentation
of vaccination with >1 dose of MMR or other live, rubella-containing vaccine adminis-
tered on or after the first birthday, b) have laboratory evidence of immunity, or c) were
born before 1957 (except women who could become pregnant). Susceptible adults born
after 1957 who do not have a medical contraindication should receive >1 dose of MMR
*CSTE recommends that states use CDC’s Epidemic Information Exchange (Epi-X ) to disseminate
outbreak information. Information on Epi-X is available at <http://www.cdc.gov/programs/
research5.htm>.
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vaccine for protection against rubella and two doses >1 month apart if at high risk for
exposure to measles (17 ). Birth before 1957 is not acceptable evidence for rubella im-
munity for women who could become pregnant.
Contraindications and Precautions
Following is a summary of contraindications and precautions for administration of
MMR vaccine. For more detailed information, consult the most recent ACIP statement
on MMR vaccination (17 ).
Allergic Reactions
MMR vaccine should not be administered to persons who have experienced severe
allergic reactions to a previous dose of a rubella-containing vaccine or to a vaccine
component (e.g., gelatin or neomycin). Allergy to egg is not a contraindication.
Pregnancy
MMR vaccine should not be administered to women known to be pregnant or at-
tempting to become pregnant. Because of the theoretical risk to the fetus, women should
be counseled to avoid becoming pregnant for 3 months after receipt of a rubella-
containing vaccine (18 ). If a pregnant woman is vaccinated or becomes pregnant within
3 weeks after receipt of vaccine, she should be counseled regarding the theoretical
basis of concern for the fetus. However, receipt of rubella-containing vaccine during
pregnancy should not ordinarily be a reason to consider termination of pregnancy.
Women who are susceptible to rubella and not vaccinated because they are pregnant
or might become pregnant within the next 3 months should be advised regarding the
potential risk for CRS and the importance of being vaccinated as soon as they are no
longer pregnant (17 ).
From January 1971 through April 1989, CDC followed to term 321 known rubella-
susceptible women who were vaccinated within 3 months before or 3 months after
conception. Ninety-four women received HPV-77 or Cendehill vaccines, one received
vaccine of unknown strain, and 226 received RA 27/3 vaccine (the only rubella vaccine
presently used in the United States). None of the 324 infants born to these mothers had
malformations compatible with CRI, but five had evidence of subclinical rubella infec-
tion, two of whom were exposed to RA 27/3 vaccine (17 ). Based on these data, the
estimated risk for serious malformations attributable to RA 27/3 vaccine ranges from
zero to 1.6% (17 ). Breast-feeding is not a contraindication to receiving MMR vaccine.
Immunodeficiency
MMR vaccine should not be administered to persons with severe immunodeficiency
from any cause. Persons with mild immunosuppression (e.g., from asymptomatic hu-
man immunodeficiency virus [HIV] infection or short-term or low-dose steroid use)
may be vaccinated.
Illness
Health-care providers should evaluate whether to administer MMR vaccine to
• persons with moderate or severe illness. Minor illnesses (e.g., otitis media or mild
upper respiratory tract infection) are not contraindications for receipt of vaccine.
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• persons with history of thrombocytopenia. The decision to vaccinate should
depend on the benefits of immunity to measles, mumps, and rubella compared
with the risks for recurrence or exacerbation of thrombocytopenia either after
vaccination or during natural infection with measles or rubella.
• persons who have received high doses of immunoglobulins. Recent evidence
indicates that high doses of immunoglobulins can inhibit the immune response to
rubella vaccine for >3 months.
Vaccine Information Statements (VIS)
The National Childhood Vaccine Injury Act (NCVIA) requires all health-care provid-
ers in the United States who administer MMR vaccine to provide a copy of the relevant
VIS to either an adult vaccinee, or in the case of a minor, to a parent or legal represen-
tative (18 ). Health-care providers are not required to obtain the signature of the pa-
tient, parent, or legal representative acknowledging receipt of the VIS. However, to
document that the VIS was given, health-care providers must note in each patient’s
permanent medical record at the time a VIS is provided the date printed on the VIS and
the date the VIS is administered to the vaccine recipient, parent, or legal representative.
NCVIA also requires that health-care providers note the following information in the
patient’s permanent medical record:
• The date of administration of the vaccine.
• The manufacturer and lot number of the vaccine.
• The name and address of the health-care provider administering the vaccine (i.e.,
the address where the record is kept; if vaccinations are administered in a
shopping mall, for example, the address should be the clinic where the permanent
record will reside).
Reporting of Adverse Events
The National Vaccine Injury Act of 1986 requires physicians and other health-care
providers who administer vaccines to maintain permanent immunization records and
to report occurrences of adverse events for selected vaccines (17 ). Serious adverse
events (i.e., all events requiring medical attention), regardless of whether they are sus-
pected to have been caused by vaccine, should be reported to the Vaccine Adverse
Event Reporting System (VAERS). VAERS forms and instructions are available in the
FDA Drug Bulletin and the Physicians’ Desk Reference or by calling the 24-hour VAERS
information recording at (800) 822-7967.
RUBELLA PREVENTION AND CONTROL AMONG WOMEN
OF CHILDBEARING AGE
Guidelines for rubella prevention and control among women of childbearing age
differ depending on the likelihood of exposure to rubella. Identifying women who could
have been exposed is critical so they can receive appropriate testing and follow-up.
Guidelines for testing and follow-up for all women of childbearing age, pregnant women
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for whom rubella exposure is unlikely, and pregnant women who might have been
exposed to rubella are outlined in the following sections.
All Women of Childbearing Age
Health-care providers who treat women of childbearing age should routinely deter-
mine rubella immunity and vaccinate those who are susceptible and not pregnant.
Proof of immunity can be either a verified record of vaccination or a positive IgG anti-
body serologic test. Rubella-susceptible women who a) do not report being pregnant,
b) are not likely to become pregnant in the next 3 months, and c) do not have other
contraindicating conditions should be vaccinated. Before vaccination, each patient
should be counseled to avoid pregnancy for 3 months after vaccination because of the
theoretical risk for vaccine virus affecting the fetus. Because routine pregnancy screen-
ing is not recommended before rubella vaccination, patients should be counseled re-
garding the theoretical risk to the fetus from inadvertent vaccination of a pregnant
woman.
Pregnant Women Without Likely Exposure
Even when no outbreaks have been reported and no rubella exposure has occurred,
health-care providers should routinely conduct a rubella IgG test for all pregnant women
at the earliest prenatal visit. A positive rubella IgG antibody test indicates rubella im-
munity, and health-care providers can assume that immunity was acquired before preg-
nancy. Women who are found to be susceptible should be monitored for signs of rubella
during pregnancy and vaccinated postpartum. Susceptible pregnant women should be
advised to avoid contact with persons with rash illness.
An IgM test should not be used to determine rubella immune status; IgM is used to
diagnose acute and recent rubella infection. The TORCH (i.e., toxoplasmosis, rubella,
cytomegalovirus, and herpes) panel includes a test for rubella IgG antibodies as well as
a test for rubella IgM antibodies. Because of the potential for false-positive IgM results,
a TORCH panel should not be used to determine rubella immunity. Rubella IgM testing
should be performed on pregnant women who report symptoms of rubella or suscep-
tible pregnant women who might have been exposed to rubella to rule out acute or
recent infection.
Screening and Follow-Up of Pregnant Women
Who Might Have Been Exposed to Rubella
Because the consequences of rubella infection during pregnancy are serious, every
effort must be made to identify all women of childbearing age exposed to a person
with confirmed, probable, or suspected rubella. Women found to be susceptible and
not pregnant should be vaccinated as outlined previously (see All Women of Childbear-
ing Age). Susceptible household contacts of pregnant women should also be vacci-
nated.
All exposed pregnant women should be screened to determine if they a) were in-
fected during pregnancy, b) are susceptible, or c) were immune before pregnancy. Be-
cause of the seriousness of CRI, immunity must be documented by a verified, dated
record of a positive serologic test. Pregnant women without documented immunity
should be tested for the presence of rubella IgG and IgM antibodies as outlined in this
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section. Identifying susceptible pregnant women is critical, so they can be isolated from
further exposure, monitored for infection, and vaccinated postpartum. Pregnant women
with evidence of infection during pregnancy should be evaluated to verify rubella in-
fection and determine gestational age at time of infection, if possible, to assess the
possibility of risk to the fetus.
Immunoglobulin (IG) does not prevent rubella or mumps infection after exposure
and is not recommended for that purpose (18 ). Administration of IG after exposure to
rubella will not prevent infection or viremia, but might modify or suppress symptoms
and create an unwarranted sense of security. Therefore, IG is not recommended for
routine postexposure prophylaxis of rubella in early pregnancy or any other circum-
stance. Infants with congenital rubella have been born to women who received IG
shortly after exposure. Administration of IG should be considered only if a pregnant
woman who has been exposed to rubella will not consider termination of pregnancy
under any circumstances. In such cases, intramuscular administration of 20 mL of IG
within 72 hours of rubella exposure might reduce — but will not eliminate — the risk for
rubella.
During an outbreak, the following steps should be taken to evaluate and follow up
with pregnant women who had contact with a person with confirmed, probable, or
suspected rubella:
• Use documented serologic test results to verify immunity. If unavailable, conduct
rubella IgG and IgM antibody testing regardless of symptom history. Pregnant
women who are exposed to rubella and who do not have documented proof of
immunity should be tested for rubella-specific IgM antibodies to identify recent
infection. Because 20%–50% of rubella cases are asymptomatic, this testing policy
is crucial to assess the possibility of risk to the fetus. Another way to identify recent
infection is to detect a significant rise in paired IgG serum. A single positive IgG
test indicates rubella immunity, but does not give information regarding the
timing of the infection. However, a significant rise in IgG antibody (determined by
testing paired sera) or positive IgM antibody test indicates recent infection.
• Recommend restricting activities to avoid exposure while waiting for serologic
test results. During this time, pregnant women should be excluded from activities
(e.g., work or school) that present the possibility of exposure to persons with
confirmed or suspected cases of rubella. Pregnant women found to be susceptible
to rubella should avoid these settings for 6 weeks (two incubation periods) after
the onset of symptoms of rubella in the last patient for whom rubella cannot be
ruled out.
• Evaluate exposed pregnant women with positive IgG titers and negative IgM to
determine if they acquired immunity before pregnancy or infection during
pregnancy. Women without previously documented immunity who were
exposed during pregnancy and >6 weeks before IgM testing could test negative
for IgM antibodies, which are normally not detectable >6 weeks after infection.
Thus, a negative rubella IgM antibody assay does not rule out infection during
pregnancy. The dates of the pregnancy, possible exposures, test(s), and history of
rash illness should be considered in assessing the possibility of risk to the fetus.
• Evaluate pregnant women with confirmed rubella to assess risk to the fetus.
Rubella infection during the first 3 months of pregnancy is associated with the
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greatest risk for CRI, and up to 90% of infants born to mothers infected during the
first 11 weeks of gestation will develop CRS. Infection late in the first half of
pregnancy is more likely to result in hearing impairment and less likely to be
associated with other defects. Although not likely to result in CRS, rubella
infection late in pregnancy can result in congenital rubella infection only.
• Pregnant women with negative IgG and negative IgM on first testing should be
retested in 10–14 days; the first specimen should be reanalyzed along with the
second specimen. A significant rise in IgG or positive IgM indicates recent
infection. If a susceptible pregnant woman continues to be directly exposed to
rubella, repeat tests of paired sera in 10–14 days to determine if infection occurs,
then every 3–4 weeks if exposure continues. Testing can be performed earlier if
pregnancy outcome might be influenced. Evaluate the infant on delivery for signs
of CRS, and vaccinate the mother postpartum.
• Recommend restricting activities for susceptible women (i.e., those without
detectable IgG and IgM antibodies), obtain follow-up serologic testing, and
vaccinate after delivery. Susceptible pregnant women should be excluded from
activities (e.g., work or school) that present the possibility of exposure to persons
with confirmed or suspected cases of rubella. Pregnant women found to be
susceptible should avoid these settings for 6 weeks (two incubation periods) after
the onset of symptoms of rubella in the last patient for whom rubella cannot be
ruled out. Household contacts or other ongoing contacts without documented
rubella immunity should be vaccinated.
• Evaluate asymptomatic, exposed pregnant women with documented history of
previous rubella immunity. Rubella reinfection is rare but has been documented
(19–22 ). Women with documentation of previous rubella immunity who are
exposed to rubella during pregnancy should consult their physicians. After
discussing the potential for reinfection, physicians might recommend acute- and
convalescent-phase IgG antibody testing or an IgM antibody test to document
whether reinfection has occurred. However, the potential for false-positive IgM
tests exists, and the potential risks and benefits of testing should be considered.
• Counsel pregnant women with documentation of previous immunity to seek
medical attention promptly if rubella-like symptoms appear. Any pregnant
woman with documented immunity and rubella-like symptoms should be
immediately evaluated by a physician to diagnose the symptoms and ensure the
health of the mother and fetus.
SURVEILLANCE FOR CONGENITAL RUBELLA SYNDROME
Consequences of CRI during pregnancy include abortion, miscarriage, stillbirth, and
a pattern of birth defects called CRS. The most common congenital defects related to
CRS are cataracts, heart defects, hearing impairment, and developmental delay. Other
less specific signs and symptoms of CRS include purpura, hepatosplenomegaly, jaun-
dice, microcephaly, meningoencephalitis, and radiolucent bone disease.
Pregnant women with known rubella exposure should receive follow-up care. Sur-
veillance for CRI and CRS should be implemented when confirmed or probable rubella
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cases are documented in a setting where pregnant women might have been exposed.
The following steps are recommended to achieve these goals:
• Follow the outcome of pregnancy for pregnant women with confirmed or
suspected rubella infection and for susceptible pregnant women with rubella
exposure. A state or local registry of pregnant women with confirmed or
suspected rubella should be established to record pregnancy outcomes (e.g.,
abortion, stillbirth, congenital rubella-associated defects) and laboratory
evaluation of infants. Because hearing impairment, cataracts, and heart defects
are common among infants with CRS, hearing and vision evaluations for infants
born to susceptible, pregnant women exposed to rubella could help identify cases
and aid early diagnosis and intervention.
• Educate and heighten awareness among health-care providers. Health-care
providers in the area of an outbreak should be made aware of the potential for CRS
births in their facilities and given information regarding the physical
manifestations of CRS and appropriate laboratory testing for infants with
suspected CRS. The classic presentation for CRS is cataracts, hearing impairment,
and congenital heart disease (especially patent ductus arteriosus or peripheral
pulmonic stenosis). Some conditions associated with CRS (e.g., hearing
impairment and developmental delay) might not be apparent at birth.
The following steps are recommended for follow-up and surveillance for CRS and
congenital rubella infection only cases:
• Discuss appropriate isolation procedures for infants with CRS and congenital
rubella infection only with health-care providers. Only persons immune to rubella
should have contact with these infants. Children with CRS should be presumed
infectious at least through age 1 year unless nasopharynx and urine cultures are
negative for virus after age 3 months. Some authorities suggest that an infant with
CRS should be considered infectious until two cultures of clinical specimens
obtained 1 month part are negative for rubella virus.
• Use universal newborn hearing screening programs to help detect CRS, where
available. Approximately 50% of states have such programs, some of which use
a combination of evoked otoacoustic emissions and auditory brainstem response
to identify hearing impairment in newborns. Because hearing impairment is the
most common single defect associated with CRS, newborns who fail hearing
screening tests should be tested for rubella-specific IgM antibodies to rule out CRS.
• Confirm the CRS or congenital rubella infection only diagnosis with laboratory
testing (see Laboratory Diagnosis of Congenital Rubella Syndrome and
Congenital Rubella Infection).
• Report all CRS and congenital rubella infection only cases to the state health
department as soon as they are suspected, even though laboratory confirmation
might be pending. State health departments should then report cases to CDC’s
Rubella Activity at (404) 639-8230. Cases are then entered into the National
Congenital Rubella Syndrome Registry. The following data are epidemiologically
important and should be collected during case investigations (additional
information can be collected at the direction of the state health department):
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— Demographic information.
— Maternal history, including a) date of rubella vaccination(s), b) dates and results
of previous serologic tests for rubella immunity, c) history or documentation of
rubella infection during pregnancy, d) history of pregnancies inside and
outside the United States, e) country of birth and length of residence in the
United States, and f) history of exposure to rubella and travel.
— Clinical details (e.g., cataracts, hearing impairment, developmental delay, type
of congenital heart defect, meningoencephalitis, microcephaly).
— Laboratory information, including types and results of laboratory testing
performed on both mother and child.
• Recommend consultation with specialists for infants with CRS, as appropriate,
based on clinical manifestations.
CONCLUSION
Rubella outbreak control is essential for eliminating indigenous rubella and pre-
venting CRS and CRI. Strategies for rubella outbreak control include defining target
populations for rubella vaccination, ensuring that susceptible persons within the target
populations are vaccinated rapidly (or excluded from exposure if a contraindication for
vaccination exists), and maintaining rubella and CRS surveillance (18 ). Control mea-
sures should be implemented as soon as a case of rubella is identified. Maintaining
control measures is essential when pregnant women are possible contacts of patients
with rubella. Susceptible pregnant women who are exposed to rubella should be thor-
oughly evaluated for possible rubella infection.
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page.
2. Go to the MMWR Continuing Education Internet site at <http://www.cdc.gov/mmwr/cme/conted.html>.
3. Select which exam you want to take and select whether you want to register for CME, CEU, or CNE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must answer all of the questions.
Questions with more than one correct answer will instruct you to “Indicate all that apply.”
6. Submit your answers no later than July 13, 2004.
7. Immediately print your Certificate of Completion for your records.
By Mail
1. Read this MMWR (Vol. 50, RR-12), which contains the correct answers to the questions beginning on the next
page.
2. Complete all registration information on the response form, including your name, mailing address, phone
number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive
continuing education credit, you must answer all of the questions. Questions with more than one correct
answer will instruct you to “Indicate all that apply.”
5. Sign and date the response form or a photocopy of the form and send no later than July 13, 2004, to
Fax: 404-639-4198 Mail: MMWR CE Credit
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1600 Clifton Rd, N.E.
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6. Your Certificate of Completion will be mailed to you within 30 days.
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Continuing Medical Education (CME).  CDC is accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to provide continuing medical education for physicians. CDC designates this educational activity for a maximum of
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hours of credit that he/she actually spent in the educational activity.
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Goal and Objectives
This MMWR provides recommendations regarding the prevention and control of rubella outbreaks in the United
States. These recommendations were prepared by CDC staff members after consultation with state and local
public health officials. The goal of this report is to improve the control of rubella in the United States. Upon
completion of this continuing education activity, the reader should be able to a) describe characteristics of recent
rubella outbreaks, b) list steps recommended for evaluation and management of a suspected rubella outbreak,
c) recognize contraindications and precautions to the use of rubella vaccine, and d) identify strategies for the
prevention of rubella among women of childbearing age.
To receive continuing education credit, please answer all of the following questions.
1. What is the most common setting for recent rubella outbreaks?
A. Elementary school.
B. Day care.
C. College dormitory.
D. Workplace.
E. Place of worship.
2. Which of the following is acceptable to establish the laboratory diagnosis of rubella virus infection?
A. Positive serologic test for rubella immunoglobulin M (IgM) antibody.
B. Significant rise between acute and convalescent titer of rubella immunoglobulin G (IgG) antibody.
C. Isolation of rubella virus from a clinical specimen.
D. Detection of rubella virus by reverse transcriptase polymerase chain reaction.
E. All of the above are acceptable to establish the laboratory diagnosis of rubella virus infection.
3. What is the most common single defect identified with congenital rubella syndrome?
A. Hearing impairment.
B. Patent ductus arteriosus.
C. Cataract.
D. Mental retardation.
E. Bone defects.
4. Which of the following is not a recommended step for managing a suspected rubella outbreak?
A. Confirm the diagnosis of rubella.
B. Vaccinate all contacts of the person with rubella regardless of previous rubella vaccination history.
C. Initiate enhanced rubella surveillance measures.
D. Conduct outreach in affected communities.
E. Develop a plan for preventing future rubella outbreaks.
5. Which of the following is a valid contraindication to the use of measles-mumps-rubella (MMR) vaccine?
A. Current treatment with antibiotics.
B. Mild asthma.
C. Severe allergic reaction to a previous dose of MMR vaccine.
D. Household contact with a pregnant woman.
E. All of the above are valid contraindications to the use of MMR vaccine.
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6. What age group currently accounts for the most reported rubella cases in the United States?
A. Infants aged <12 months.
B. Children aged 1–4 years.
C. Children aged 5–14 years.
D. Adults aged >15 years.
E. No specific age group accounts for the most reported rubella cases in the United States.
7. What is a value of molecular typing of rubella virus?
A. To determine the origin of the virus.
B. To determine the pathogenicity of the virus.
C. To estimate the potential efficacy of rubella vaccine.
D. To determine the susceptibility of the virus to antiviral agents.
E. To identify viruses that could be included in new vaccines.
8. What information should be collected from all persons with rubella?
A. Date of onset of illness.
B. Possible setting of rubella transmission.
C. Results of laboratory testing.
D. Recent travel history.
E. All of the above information should be collected from persons with rubella.
9. Which of the following is not acceptable as evidence of rubella immunity in a woman of childbearing age?
A. Documentation of one dose of MMR vaccine on or after the first birthday.
B. Documentation of two doses of MMR vaccine on or after the first birthday.
C. Positive serologic test for rubella IgG antibody.
D. Birth before 1957.
E. All of the above are acceptable as evidence of rubella immunity in a woman of childbearing age.
10. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
11. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.
C. Patient care — primary care clinic or office.
D. Laboratory/pharmacy.
E. Public health.
F. Other.
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12. I plan to use these recommendations as the basis for . . . (Indicate all that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
13. Each month, to approximately how many persons do you administer rubella vaccine?
A. None
B. 1–5.
C. 6–20.
D. 21–50.
E. 50–100.
F. >100.
14. How much time did you spend reading this report and completing the exam?
A. Less than 1 hour.
B. 1–1.5 hours.
C. 1.5–2 hours.
D. More than 2 hours.
15. After reading this report, I am confident I can describe characteristics of recent rubella outbreaks.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can list steps recommended for evaluation and management of
a suspected rubella outbreak.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can recognize contraindications and precautions to the use of
rubella vaccine.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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18. After reading this report, I am confident I can identify strategies for the prevention of rubella among
women of childbearing age.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal).
C. Coworker/supervisor.
D. MMWR subscription.
E. Other.
23. The availability of continuing education credit was important to my decision to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–9.
1. D; 2. E; 3. A; 4. B; 5. C; 6. D; 7. A; 8. E; 9. D.
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2. indicate your choice of CME, CEU, or CNE credit;
3. answer all of the test questions;
4. sign and date this form or a photocopy;
5. submit your answer form by July 13, 2004.
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